To determine whether anti-CD83 induced changes in the studies above would provide beneficial responses relevant for the treatment of autoimmune diseases, we assessed whether DCR-5 could reduce the severity of CIA developed by DBA/1 mice using the treatment regimens outlined in Figure 9A. Here, CD83 is linked to autoimmune disease.